CXCR2 and neoplasm: Treatment of tumor-bearing mice with the CXCR2 inhibitor SX-682 and anti-CXCR2 antibodies decreased the migration of MDSCs, suppressed the tumor-promoting response, and improved the efficacy of anti-PD1 therapy [119,143].